} Next step in fight against liver diseases - Strand

4/18/2018 - Posted in  Pharmaceutical Affairs

Next step in fight against liver diseases

Our expert's opinion

"Belgian biotech Promethera makes another step in becoming the leading drug development organization in severe liver diseases utilizing cell-based and biologically-driven approaches."

- Matthieu Saintmard, Senior Associate

Promethera acquires Swiss biopharmaceutical firm Baliopharm


Promethera Biosciences has acquired Baliopharm, a Swiss biopharmaceutical company focused on the development of targeted biological therapies for immune mediated inflammatory diseases and cancer.

The transaction complements Promethera’s pipeline with an innovative antibody-based drug candidate that specifically binds to the tumor necrosis factor receptor 1 (TNF-R1).

Combining this novel therapeutic strategy with Promethera’s unique liver cell-based therapies could provide improved treatment option for patients suffering from Nonalcoholic steatohepatitis (NASH) and potentially other severe liver diseases. Financial details of the transaction were not disclosed.

With the TNF-alpha pathway and its Receptor 1 (R1) being implicated in the progression of many inflammatory diseases, including chronic liver diseases leading to fibrosis, a therapeutic antibody approach is a valuable strategy in its own right as well as in combination with Promethera’s cell-based medicines such as the HepaStem technology.

Through today’s transaction, Promethera gains control over Baliopharm’s entire antibody development programs in particular the one focused on establishing a unique next-generation and selective TNF-R1 inhibitor including the novel, antibody based monovalent drug candidate Atrosimab.

Promethera Biosciences president and CEO Dr John Tchelingerian said: “The acquisition of Baliopharm immediately adds very promising antibody assets to our cell-based pipeline and diversifies our therapeutic strategy in NASH by giving us a proprietary combination therapy option.

With the development of our cell-based therapy HepaStem advancing rapidly towards clinical trials in this indication, the opportunity to strengthen our portfolio with the complementary and potentially synergistic approach that Atrosimab represents is highly valuable and unique from an IP and scientific perspective.”

Baliopharm CEO Dr Andreas Herrmann said: “Today’s announcement is a testament to the strong science that is the foundation of our next-generation anti-TNF R1 development program using a novel therapeutic antibody format, Atrosimab.

Baliopharm is a biotechnology company focusing on the development of novel antibody-based therapeutics for the treatment of autoimmune diseases like rheumatoid arthritis, Crohn`s disease, psoriasis and multiple sclerosis, and for cancer.

Baliopharm’s antibody pipeline consisting of two selective TNF-R1 antagonists, Atrosab and Atrosimab and the bispecific anti-CD20/CD95 antibody construct, Novotarg.


Source: PBR Drug Discovery

Other insights in Pharmaceutical Affairs